Asia Pacific Menopausal Disorder Treatment Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
USD
2,026.59 Million
USD
4,097.76 Million
2021
2029
 Período de previsão |
2022 –2029 |
 Tamanho do mercado (ano base ) | USD 2,026.59 Million |
 Tamanho do mercado ( Ano de previsão) | USD 4,097.76 Million |
 CAGR |
% |
| Principais participantes do mercado |
Mercado de tratamento para perturbações da menopausa na Ásia-Pacífico, por fases (menopausa, pós-menopausa, perimenopausa), tipo (terapia hormonal e terapia não hormonal), sintomas da menopausa (sintomas vasomotores, vaginite atrófica, osteoporose, dores nas articulações, aumento de peso, dispareunia, depressão, Outros), Forma de dosagem ( comprimido , cremes, géis, anéis/insertos, adesivos/filmes, injecção, spray, outros), Via de administração (oral, vaginal, transdérmica, parentérica), Utilizadores finais (hospitais, clínicas especializadas, Homecare, Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online, Outros) – Tendências do Setor e Previsão para 2029
Análise de Mercado e Tamanho
A menopausa é um dos períodos mais exigentes fisicamente na vida de uma mulher, levando as empresas farmacêuticas de todo o mundo a criar medicamentos eficazes para a tratar e problemas relacionados. A menopausa, também conhecida como período climático, ocorre quando os períodos menstruais da mulher deixam de ocorrer de forma permanente. Inúmeras alterações significativas ocorrem no corpo feminino durante este período, resultando no aparecimento de diversas doenças. Os problemas da menopausa estão a tornar-se mais comuns em todas as partes do mundo, e as organizações de saúde apoiam o desenvolvimento e a utilização de medicamentos que os possam tratar eficazmente. Isto levou também as empresas farmacêuticas a desenvolver e comercializar medicamentos que aliviam os sintomas a longo prazo das doenças da menopausa nas mulheres e não afetam a sua saúde durante ou após o tratamento.
A Data Bridge Market Research analisa que o mercado de tratamento de distúrbios da menopausa na Ásia-Pacífico foi avaliado em 2.026,59 milhões de dólares em 2021 e deverá atingir os 4.097,76 milhões de dólares até 2029, registando um CAGR de 9,20% durante o período previsto de 2022 a 2029. O mercado O relatório com curadoria da equipa de pesquisa de mercado da Data Bridge inclui uma análise aprofundada de especialistas, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.
Âmbito do Relatório e Segmentação de Mercado
|
Métrica de Reporte |
Detalhes |
|
Período de previsão |
2022 a 2029 |
|
Ano base |
2021 |
|
Anos históricos |
2020 (Personalizável para 2019 - 2014) |
|
Unidades quantitativas |
Receita em milhões de dólares americanos, volumes em unidades, preços em dólares americanos |
|
Segmentos abrangidos |
Estágios (menopausa, pós-menopausa, perimenopausa), tipo (terapia hormonal e terapia não hormonal), sintomas da menopausa (sintomas vasomotores, vaginite atrófica, osteoporose, dores nas articulações, aumento de peso, dispareunia, depressão, outros), forma de posologia (comprimido, cremes , Géis, Anéis/Inserção, Adesivo/Película, Injecção, Spray, Outros), Via de Administração (Oral, Vaginal, Transdérmica, Parentérica), Utentes Finais (Hospitais, Clínicas Especializadas, Assistência Domiciliária, Outros), Canal de Distribuição (Hospital Farmácia, Farmácia de Retalho, Farmácia Online, Outros) |
|
Países abrangidos |
China, Japão, Índia, Coreia do Sul, Singapura, Malásia, Austrália, Tailândia, Indonésia, Filipinas, Resto da Ásia-Pacífico (APAC) na Ásia-Pacífico (APAC). |
|
Atores do mercado abrangidos |
Eli Lilly and Company (EUA), Novo Nordisk A/S (Dinamarca), Allergan (Irlanda), Dr. Reddy’s Laboratories Ltd. (Índia), GlaxoSmithKline plc (Reino Unido), Mylan NV (EUA), Pfizer Inc. (EUA ) , Ipsen Pharma (França), Abbott (EUA), Besins Healthcare (Bélgica) |
|
Oportunidades de Mercado |
|
Definição de Mercado
A síndrome da menopausa refere-se aos sintomas que acompanham as alterações fisiológicas que ocorrem no organismo da mulher quando os seus anos reprodutivos chegam ao fim. A menopausa é uma deficiência hormonal feminina natural que ocorre entre os 45 e os 55 anos. Os ovários tornam-se gradualmente menos ativos e produzem menos hormonas sexuais durante este período (estrogénio e progesterona). Como resultado, a menstruação já não é possível. Se uma mulher não tiver um ciclo menstrual durante um ano e não existir uma causa subjacente, é geralmente considerada menopausada.
Dinâmica do mercado de tratamento das perturbações da menopausa na Ásia-Pacífico
Motoristas
- Aumento da prevalência de perturbações da menopausa
Estima-se que a crescente prevalência de perturbações da menopausa impulsione o crescimento do mercado de tratamento das perturbações da menopausa. Juntamente com isto, o aumento dos casos de hormonoterapia, radioterapia e histerectomia influenciará a taxa de crescimento do mercado.
- Aumento do investimento em infraestruturas de saúde
Outro fator significativo que influencia a taxa de crescimento do mercado de tratamento das perturbações da menopausa é o aumento dos gastos com a saúde, o que ajuda a melhorar as suas infraestruturas.
Além disso, as crescentes iniciativas de organizações públicas e privadas para disseminar a sensibilização e o avanço tecnológico irão expandir o mercado de tratamento das perturbações da menopausa. Além disso, o elevado rendimento disponível e o estilo de vida em constante mudança irão expandir o mercado de tratamento das perturbações da menopausa. Juntamente com isto, o aumento da população geriátrica e o aumento de casos de distúrbios hormonais aumentarão a taxa de crescimento do mercado.
Oportunidades
- Aumento do número de atividades de investigação e desenvolvimento
Além disso, o crescimento do mercado é impulsionado pelo aumento do número de atividades de investigação e desenvolvimento. Isto proporcionará oportunidades benéficas para o crescimento do mercado de tratamento das perturbações da menopausa. Juntamente com isto, o aumento das aprovações de medicamentos e o lançamento de produtos inovadores impulsionarão ainda mais a taxa de crescimento do mercado.
Além disso, o aumento do investimento no desenvolvimento de tecnologias avançadas e o aumento do número de mercados emergentes proporcionarão oportunidades benéficas para o crescimento do mercado de tratamento das perturbações da menopausa durante o período previsto.
Restrições/Desafios
Por outro lado, o elevado custo associado à terapia hormonal irá obstruir a taxa de crescimento do mercado. A escassez de profissionais qualificados e a falta de infraestruturas de saúde nas economias em desenvolvimento vão desafiar o mercado de tratamento das perturbações da menopausa. Além disso, a falta de sensibilização e os efeitos secundários dos medicamentos funcionarão como restrições e impedirão ainda mais a taxa de crescimento do mercado durante o período previsto de 2022-2029.
Este relatório de mercado de tratamento de distúrbios da menopausa fornece detalhes de novos desenvolvimentos recentes, regulamentos comerciais, análise de importação e exportação, análise de produção, otimização da cadeia de valor, quota de mercado, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, análise estratégica do crescimento do mercado, tamanho do mercado, crescimento do mercado de categorias, nichos de aplicação e dominância, aprovações de produtos, lançamentos de produtos, expansões geográficas, inovações tecnológicas no mercado. Para mais informações sobre o mercado de tratamento de distúrbios da menopausa, contacte a Data Bridge Market Research para um briefing de analista.
Análise epidemiológica do doente
O mercado de tratamento das doenças da menopausa também fornece análises de mercado detalhadas para análise de pacientes, prognóstico e curas. Prevalência, incidência, mortalidade e taxas de adesão são algumas das variáveis de dados disponíveis no relatório. As análises de impacto direto ou indireto da epidemiologia no crescimento do mercado são analisadas para criar um modelo estatístico multivariado de coorte mais robusto para prever o mercado no período de crescimento.
Impacto da COVID-19 no mercado de tratamento das perturbações da menopausa na Ásia-Pacífico
O mercado de tratamento das perturbações da menopausa foi prejudicado pela pandemia de COVID-19, o que resultou no encerramento temporário das unidades fabris e na queda da procura. Enquanto o mundo tentava impedir a propagação do SARS-CoV-2, as principais corporações trabalhavam para reforçar as suas redes de abastecimento e acelerar as suas operações para evitar mais perdas. As organizações de saúde de vários países do mundo estavam a ter dificuldades em continuar as suas atividades na cadeia de abastecimento. A lentidão da cadeia de abastecimento também prejudicou o mercado de tratamento das perturbações da menopausa. No entanto, agora que as vacinas contra a COVID-19 estão prontamente disponíveis, várias autoridades estão a tentar garantir que os medicamentos e vacinas que salvam vidas são fornecidos sem interrupções. Como resultado, espera-se que o mercado de tratamento das perturbações da menopausa recupere mais rapidamente nos próximos anos.
Âmbito do mercado de tratamento das perturbações da menopausa na Ásia-Pacífico
O mercado de tratamento das perturbações da menopausa está segmentado com base nas fases, tipo, sintomas da menopausa, forma farmacêutica, via de administração, utilizadores finais e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar segmentos de baixo crescimento nos setores e fornecerá aos utilizadores uma visão geral e informações valiosas do mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.
Estágios
- Menopausa
- Pós-menopausa
- Perimenopausa
Tipo
- Terapia Hormonal
- Estrogênio
- Progesterona
- Combinação
- Terapia Não Hormonal
- Antidepressivos
- Outros
Sintomas da menopausa
- Sintomas vasomotores
- Vaginite atrófica
- Osteoporose
- Dor nas articulações
- Ganho de peso
- Dispareunia
- Depressão
- Outros
Forma de dosagem
- Comprimido
- Cremes
- Géis
- Anéis/Inserção
- Patch/Filme
- Injeção de tiro
- Pulverizar
- Outros
Via de Administração
- Oral
- Vaginal
- Transdérmico
- Parenteral
Utilizadores finais
- Hospitais
- Clínicas especializadas
- Assistência Domiciliária
- Outros
Canal de Distribuição
- Farmácia Hospitalar
- Farmácia de retalho
- Farmácia Online
- Outros
Análise regional/perspetivas do mercado de tratamento das perturbações da menopausa na Ásia-Pacífico
O mercado de tratamento das perturbações da menopausa é analisado e são fornecidos insights e tendências sobre o tamanho do mercado por país, fases, tipo, sintomas da menopausa, forma farmacêutica, via de administração, utilizadores finais e canal de distribuição, conforme referenciado acima.
Os países abrangidos pelo relatório de mercado de tratamento das perturbações da menopausa na Ásia-Pacífico são a China, o Japão, a Índia, a Coreia do Sul, Singapura, a Malásia, a Austrália, a Tailândia, a Indonésia, as Filipinas e o Resto da Ásia-Pacífico (APAC) na Ásia -Pacífico ( (Ásia-Pacífico).
O Japão domina o mercado de tratamento das perturbações da menopausa na Ásia-Pacífico devido à presença de grandes players e ao aumento dos gastos em saúde nesta região.
A secção do relatório sobre os países também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado nacional que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a montante e a jusante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade de marcas da Ásia-Pacífico e os seus desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, ao impacto de tarifas domésticas e rotas comerciais são considerados ao fornecer uma análise de previsão dos dados do país .
Análise do cenário competitivo e da quota de mercado do tratamento da perturbação da menopausa na Ásia-Pacífico
O panorama competitivo do mercado de tratamento das perturbações da menopausa fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença na Ásia-Pacífico, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento do produto, amplitude e amplitude do produto , domínio da aplicação. Os pontos de dados fornecidos acima estão apenas relacionados com o foco das empresas relacionadas com o mercado de tratamento das perturbações da menopausa.
Alguns dos principais participantes que operam no mercado de tratamento das perturbações da menopausa são:
- Mylan NV (EUA)
- Pfizer Inc. (EUA)
- GlaxoSmithKline plc (Reino Unido)
- Eli Lilly and Company (EUA)
- Abbott (EUA)
- Novo Nordisk A/S (Dinamarca)
- Allergan (Irlanda)
- Dr. Reddy's Laboratories Ltd. (Índia)
- Ipsen Pharma (França)
- Besins Healthcare (Bélgica)
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 STAGES OF MENOPAUSAL DISORDER TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: REGULATIONS
6 IMPACT OF COVID-19 ON ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET
6.1 PRICE IMPACT
6.2 MPACT ON SUPPLY CHAIN
6.3 IMPACT ON DEMAND
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING CASES OF CHEMOTHERAPY, RADIATION THERAPY AND HYSTERECTOMY
7.1.2 GROWING CASES OF HORMONE RELATED DISORDERS IN WOMEN
7.1.3 VULNERABLE AGING POPULATION OF MENOPAUSE WOMEN
7.1.4 INCREASING ASIA-PACIFIC HEALTHCARE EXPENDITURE
7.1.5 PRESENCE OF FAVOURABLE REIMBURSEMENT
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS OF MEDICATION
7.2.2 INADEQUATE KNOWLEDGE ABOUT MENOPAUSE IN SOME DEVELOPING COUNTRIES
7.2.3 HIGH COST OF HORMONAL THERAPY
7.3 OPPORTUNITIES
7.3.1 RISING GOVERNMENT INITIATIVES TO PROMOTE WOMEN’S HEALTH
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 RISING AWARENESS ABOUT THE TREATMENT
7.3.4 PRESENCE OF STRONG PRODUCT PIPELINE
7.4 CHALLENGES
7.4.1 AVAILABILITY OF ALTERNATIVES
7.4.2 PATENT EXPIRY
7.4.3 SOCIAL CONCERN REGARDING MENOPAUSAL SYMPTOMS DISCUSSION
8 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES
8.1 OVERVIEW
8.2 MENOPAUSE
8.3 POSTMENOPAUSE
8.4 PERIMENOPAUSE
9 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 HORMONAL THERAPY
9.2.1 ESTROGEN
9.2.1.1β-Estradiol
9.2.1.1.1 Minivelle
9.2.1.1.2 Others
9.2.1.2 Conjugated Estrogens
9.2.1.2.1 Premarin
9.2.1.2.2 Enjuvia
9.2.1.2.3 Others
9.2.1.3 Estradiol Hemihydrate
9.2.1.3.1 Vagifem
9.2.1.3.2 Others
9.2.1.4 Esterified Estrogens
9.2.1.5 Estradiol Acetate
9.2.1.5.1 Femring
2.2.1.5.2 Others
9.2.1.6 Estropipate
9.2.1.7 Estetrol (Donesta)
9.2.2 COMBINED ESTROGENS & PROGESTOGEN DRUGS
9.2.2.1β-Estradiol (E) + Norethindrone Acetate (P)
9.2.2.1.1 Combipatch
9.2.2.1.2 Estalis
9.2.2.1.3 Others
9.2.2.2 Ethinyl Estradiol (E) + Norethindrone Acetate (P)
9.2.2.2.1 Minastrin
9.2.2.2.2 Others
9.2.2.3 Conjugated Estrogens (E) + Medroxyprogestrone Acetate (P)
9.2.2.3.1 Premphase/Prempro
9.2.2.3.2 Others
9.2.3 PROGESTOGENS
9.2.3.1 Medroxyprogesterone Acetate
9.2.3.1.1 Provera
9.2.3.1.2 Others
9.2.3.2 Micronized Progesterone
9.2.4 OTHERS
9.3 NON HORMONAL THERAPY
9.3.1 MEDICATION
9.3.1.1 Anti-Depressants
9.3.1.1.1 Brisdelle (Paroxetine)
9.3.1.1.2 Zoloft
9.3.1.1.3 Others
9.3.1.2 Ospemifene / Osphena
9.3.1.3 Gabapentin
9.3.1.4 Clonidine
9.3.1.5 Others
9.3.2 SUPPLEMENTS
9.3.2.1 Herbal Supplements
9.3.2.1.1 Ginseng
9.3.2.1.2 Ashwagandha
9.3.2.1.3 Others
9.3.2.2 Vitamin D
9.3.2.3 Others
10 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS
10.1 OVERVIEW
10.2 VASOMOTOR SYMPTOMS
10.3 ATROPHIC VAGINITS
10.4 OSTEOPOROSIS
10.5 JOINT PAIN
10.6 WEIGHT GAIN
10.7 DYSPAREUNIA
10.8 DEPRESSION
10.9 OTHERS
11 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM
11.1 OVERVIEW
11.2 TABLETS
11.3 CREAMS
11.4 GELS
11.5 RINGS/INSERTS/INSERTS
11.6 PATCH/FILMS
11.7 INJECTION SHOT
11.8 SPRAY
11.9 OTHERS
12 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.3 VAGINAL
12.4 TRANSDERMAL
12.5 PARENTERAL
12.5.1 SUBCUTANEOUS
12.5.2 INTRAVENOUS
12.5.3 OTHERS
13 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
14 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY GEOGRAPHY
15.1 ASIA PACIFIC
15.1.1 JAPAN
15.1.2 CHINA
15.1.3 AUSTRALIA
15.1.4 INDIA
15.1.5 SOUTH KOREA
15.1.6 SINGAPORE
15.1.7 INDONESIA
15.1.8 THAILAND
15.1.9 MALAYSIA
15.1.10 PHILIPPINES
15.1.11 VIETNAM
15.1.12 REST OF ASIA PACIFIC
16 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 NOVARTIS AG
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 NOVO NORDISK A/S
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 MYLAN N.V.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 DR. REDDY’S LABORATORIES LTD.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 ELI LILLY AND COMPANY
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 ABBOTT
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 IPSEN PHARMA
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENTS
18.11 GLAXOSMITHKLINE PLC
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 BESINS HEALTHCARE
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 THERAPEUTICSMD, INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 DUCHESNAY USA
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 FERVENT PHARMACEUTICALS INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENTS
18.17 MITHRA PHARMACEUTICALS
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 KANDY THERAPEUTICS
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SEBELA PHARMACEUTICALS
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 SOJOURNIX INC.
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 MEDICINES SUBJECTED TO PATENT EXPIRY
TABLE 3 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES 2019-2027 (USD MILLION)
TABLE 4 ASIA-PACIFIC MENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 5 ASIA-PACIFIC POSTMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 6 ASIA-PACIFIC PERIMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 7 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2019-2027 (USD MILLION)
TABLE 8 ASIA-PACIFIC HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 9 ASIA-PACIFIC HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 10 ASIA-PACIFIC HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 11 ASIA-PACIFIC 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 12 ASIA-PACIFIC CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 13 ASIA-PACIFIC ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 14 ASIA-PACIFIC ESTRADIOL ACETATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 15 ASIA-PACIFIC HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 16 ASIA-PACIFIC 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 17 ASIA-PACIFIC ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 18 ASIA-PACIFIC CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 19 ASIA-PACIFIC HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC NON HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 22 ASIA-PACIFIC NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 23 ASIA-PACIFIC NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 24 ASIA-PACIFIC ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 25 ASIA-PACIFIC NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 26 ASIA-PACIFIC HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 27 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS 2019-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC VASOMOTOR SYMPTOMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC ATROPHIC VAGINITIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC OSTEOPOROSIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 31 ASIA-PACIFIC JOINT PAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 32 ASIA-PACIFIC WEIGHT GAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 33 ASIA-PACIFIC DYSPAREUNIA IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 34 ASIA-PACIFIC DEPRRESSION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 35 ASIA-PACIFIC OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 36 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM 2019-2027 (USD MILLION)
TABLE 37 ASIA-PACIFIC TABLETS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 38 ASIA-PACIFIC CREAMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 39 ASIA-PACIFIC GELS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 40 ASIA-PACIFIC RINGS/INSERTS/INSERTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 41 ASIA-PACIFIC PATCH/FILMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 42 ASIA-PACIFIC INJECTION SHOT IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 43 ASIA-PACIFIC SPRAY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 44 ASIA-PACIFIC OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 45 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 46 ASIA-PACIFIC ORAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 47 ASIA-PACIFIC VAGINAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 48 ASIA-PACIFIC TRANSDERMAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 49 ASIA-PACIFIC PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 50 ASIA-PACIFIC PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 51 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER 2019-2027 (USD MILLION)
TABLE 52 ASIA-PACIFIC HOSPITAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 53 ASIA-PACIFIC CLINICS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 54 ASIA-PACIFIC HOME HEALTHCARE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 55 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBITION CHANNEL, 2019-2027 (USD MILLION)
TABLE 56 ASIA-PACIFIC HOSPITAL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 57 ASIA-PACIFIC RETAIL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 58 ASIA-PACIFIC ONLINE PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 59 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 60 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 61 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 62 ASIA- PACIFIC HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 63 ASIA- PACIFIC HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 64 ASIA- PACIFIC 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 65 ASIA- PACIFIC CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 66 ASIA- PACIFIC ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 67 ASIA- PACIFIC ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 68 ASIA- PACIFIC ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 69 ASIA- PACIFIC HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 70 ASIA- PACIFIC 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 71 ASIA- PACIFIC ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 72 ASIA- PACIFIC CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 73 ASIA- PACIFIC HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 74 ASIA- PACIFIC MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 75 ASIA- PACIFIC NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 76 ASIA- PACIFIC NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 77 ASIA- PACIFIC ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 78 ASIA- PACIFIC NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 79 ASIA- PACIFIC HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 80 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 81 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 82 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 83 ASIA- PACIFIC PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 84 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 85 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 86 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 87 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 88 JAPAN HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 89 JAPAN HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 90 JAPAN 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 91 JAPAN CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 92 JAPAN ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 93 JAPAN ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 94 JAPAN ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 95 JAPAN HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 96 JAPAN 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 97 JAPAN ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 98 JAPAN CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 99 JAPAN HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 100 JAPAN MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 101 JAPAN NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 102 JAPAN NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 103 JAPAN ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 104 JAPAN NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 105 JAPAN HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 106 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 107 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 108 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 109 JAPAN PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 110 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 111 JAPAN MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 112 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 113 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 114 CHINA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 115 CHINA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 116 CHINA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 117 CHINA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 118 CHINA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 119 CHINA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 120 CHINA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 121 CHINA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 122 CHINA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 123 CHINA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 124 CHINA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 125 CHINA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 126 CHINA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 127 CHINA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 128 CHINA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 129 CHINA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 130 CHINA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 131 CHINA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 132 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 133 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 134 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 135 CHINA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 136 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 137 CHINA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 138 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 139 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 140 AUSTRALIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 141 AUSTRALIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 142 AUSTRALIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 143 AUSTRALIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 144 AUSTRALIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 145 AUSTRALIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 146 AUSTRALIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 147 AUSTRALIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 148 AUSTRALIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 149 AUSTRALIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 150 AUSTRALIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 151 AUSTRALIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 152 AUSTRALIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 153 AUSTRALIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 154 AUSTRALIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 155 AUSTRALIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 156 AUSTRALIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 157 AUSTRALIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 158 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 159 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 160 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 161 AUSTRALIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 162 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 163 AUSTRALIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 164 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 165 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 166 INDIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 167 INDIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 168 INDIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 169 INDIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 170 INDIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 171 INDIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 172 INDIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 173 INDIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 174 INDIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 175 INDIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 176 INDIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 177 INDIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 178 INDIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 179 INDIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 180 INDIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 181 INDIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 182 INDIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 183 INDIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 184 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 185 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 186 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 187 INDIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 188 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 189 INDIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 190 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 191 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 192 SOUTH KOREA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 193 SOUTH KOREA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 194 SOUTH KOREA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 195 SOUTH KOREA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 196 SOUTH KOREA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 197 SOUTH KOREA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 198 SOUTH KOREA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 199 SOUTH KOREA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 200 SOUTH KOREA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 201 SOUTH KOREA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 202 SOUTH KOREA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 203 SOUTH KOREA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 204 SOUTH KOREA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 205 SOUTH KOREA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 206 SOUTH KOREA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 207 SOUTH KOREA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 208 SOUTH KOREA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 209 SOUTH KOREA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 210 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 211 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 212 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 213 SOUTH KOREA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 214 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 215 SOUTH KOREA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 216 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 217 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 218 SINGAPORE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 219 SINGAPORE HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 220 SINGAPORE 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 221 SINGAPORE CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 222 SINGAPORE ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 223 SINGAPORE ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 224 SINGAPORE ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 225 SINGAPORE HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 226 SINGAPORE 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 227 SINGAPORE ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 228 SINGAPORE CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 229 SINGAPORE HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 230 SINGAPORE MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 231 SINGAPORE NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 232 SINGAPORE NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 233 SINGAPORE ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 234 SINGAPORE NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 235 SINGAPORE HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 236 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 237 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 238 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 239 SINGAPORE PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 240 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 241 SINGAPORE MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 242 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 243 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 244 INDONESIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 245 INDONESIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 246 INDONESIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 247 INDONESIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 248 INDONESIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 249 INDONESIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 250 INDONESIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 251 INDONESIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 252 INDONESIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 253 INDONESIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 254 INDONESIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 255 INDONESIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 256 INDONESIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 257 INDONESIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 258 INDONESIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 259 INDONESIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 260 INDONESIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 261 INDONESIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 262 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 263 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 264 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 265 INDONESIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 266 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 267 INDONESIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 268 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 269 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 270 THAILAND HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 271 THAILAND HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 272 THAILAND 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 273 THAILAND CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 274 THAILAND ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 275 THAILAND ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 276 THAILAND ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 277 THAILAND HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 278 THAILAND 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 279 THAILAND ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 280 THAILAND CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 281 THAILAND HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 282 THAILAND MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 283 THAILAND NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 284 THAILAND NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 285 THAILAND ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 286 THAILAND NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 287 THAILAND HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 288 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 289 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 290 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 291 THAILAND PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 292 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 293 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 294 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 295 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 296 THAILAND HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 297 THAILAND HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 298 THAILAND 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 299 THAILAND CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 300 THAILAND ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 301 THAILAND ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 302 THAILAND ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 303 THAILAND HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 304 THAILAND 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 305 THAILAND ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 306 THAILAND CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 307 THAILAND HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 308 THAILAND MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 309 THAILAND NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 310 THAILAND NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 311 THAILAND ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 312 THAILAND NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 313 THAILAND HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 314 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 315 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 316 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 317 THAILAND PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 318 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 319 THAILAND MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 320 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 321 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 322 PHILIPPINES HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 323 PHILIPPINES HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 324 PHILIPPINES 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 325 PHILIPPINES CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 326 PHILIPPINES ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 327 PHILIPPINES ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 328 PHILIPPINES ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 329 PHILIPPINES HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 330 PHILIPPINES 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 331 PHILIPPINES ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 332 PHILIPPINES CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 333 PHILIPPINES HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 334 PHILIPPINES MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 335 PHILIPPINES NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 336 PHILIPPINES NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 337 PHILIPPINES ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 338 PHILIPPINES NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 339 PHILIPPINES HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 340 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 341 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 342 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 343 PHILIPPINES PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 344 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 345 PHILIPPINES MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 346 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
TABLE 347 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 348 VIETNAM HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 349 VIETNAM HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 350 VIETNAM 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 351 VIETNAM CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 352 VIETNAM ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 353 VIETNAM ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 354 VIETNAM ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 355 VIETNAM HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 356 VIETNAM 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 357 VIETNAM ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 358 VIETNAM CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 359 VIETNAM HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 360 VIETNAM MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 361 VIETNAM NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 362 VIETNAM NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 363 VIETNAM ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 364 VIETNAM NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 365 VIETNAM HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 366 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS, 2018-2027 (USD MILLION)
TABLE 367 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)
TABLE 368 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 369 VIETNAM PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 370 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 371 VIETNAM MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 372 REST OF ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 11 GROWING CASES OF HORMONE RELATED DISORDERS AND INCREASING CASES OF CHEMOTHERAPY, RADIATION THERPAY AND HYSTERECTOMY IS DRIVING THE ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 MENOPAUSE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET
FIGURE 14 PER CAPITA HEALTHCARE EXPENDITURE IN 2018 (USD)
FIGURE 15 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, 2019
FIGURE 16 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, 2019-2027 (USD MILLION)
FIGURE 17 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, CAGR (2020-2027)
FIGURE 18 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, 2019
FIGURE 20 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION)
FIGURE 21 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 22 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, 2019
FIGURE 24 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, 2019-2027 (USD MILLION)
FIGURE 25 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, CAGR (2020-2027)
FIGURE 26 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY MENOPAUSE SYMPTOMS, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, 2019
FIGURE 28 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, 2019-2027 (USD MILLION)
FIGURE 29 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, CAGR (2020-2027)
FIGURE 30 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 32 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 33 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 34 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, 2019
FIGURE 36 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 37 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 38 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 40 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 41 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBITION CHANNEL, CAGR (2020-2027)
FIGURE 42 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY DISTRIBITION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 44 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 45 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 46 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 47 ASIA- PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: BY STAGES (2020-2027)
FIGURE 48 ASIA-PACIFIC MENOPAUSAL DISORDER TREATMENT MARKET: COMPANY SHARE 2019 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
